For breast cancer normal-tumor differentiation, CXCL14, MSLN, LCN2, and MED1 emerged as significant predictors, supported by evidence of their differential expression and involvement in tumor progression [28–31]. This evidence concerns the gene MSLN and breast carcinoma.